- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03336632
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
Chidamide Plus Post-transplantation Cyclophosphamide and Cyclosporine to Prevent Graft-versus-host Disease After Myeloablative Conditioning, Matched Peripheral-blood Stem-cell Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible patients were aged 16 to 65 years, diagnosed with hematologic malignancy, and had a Karnofsky performance score of ≥70% and were candidates for myeloablative HCT. A 8/8 HLA allelic match between the donor and the recipient at HLA-A, HLA-B, HLA-C, and HLA-DRB1 by high-resolution typing was required. The graft source was PBSC.
Patients received a myeloablative conditioning regimen consisting of oral chidamide given twice weekly at a dose of 20 mg from day -7 to 2 weeks post transplantation, intravenous busulfan 3.2 mg/kg from day -6 to -3, intravenous fludarabine 30 mg/m2 and cytarabine 1g/m2 respectively from day -6 to -2. PBSCs were infused on day 0. GVHD prophylaxis was post-transplantation cyclophosphamide (50 mg/kg on day +3, +4) and cyclosporine (started from day +5). In the absence of GVHD, cyclosporine tapering started on day +100 and discontinued on day +180. Minimal residual disease (MRD) was determined by multi-parameter flow cytometry.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jie Ji, MD
- Phone Number: 86-28-85422373
- Email: jieji@scu.edu.cn
Study Contact Backup
- Name: Ting Liu, MD PHD
- Phone Number: 86-28-85422370
- Email: liuting@scu.edu.cn
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610044
- West China Hospital of Sichuan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 16 years or older, and ≤ 65 years at time of enrollment
- Signed informed consent
- Hematologic disorder requiring allogeneic hematopoietic cell transplantation
- Left ventricular ejection fraction (LVEF) ≥ 45% by multiple uptake gated acquisition (MUGA) scan or echocardiogram
- Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing lung capacity oxygenation (DLCO) adjusted ≥ 50% of predicted values on pulmonary function tests
- Transaminases (AST, ALT) < 3 times upper limit of normal (ULN) values
- Creatinine clearance calculated ≥ 50 mL/min
- Karnofsky Performance Status Score ≥ 60%.
- Human leukocyte antigen (HLA) matched 8/ (A, B, C, DRB1) related or unrelated donor
Exclusion Criteria:
- Active infection not controlled with appropriate antimicrobial therapy HIV, hepatitis B (HBcAb positive but HBsAg negative with undetectable viral load are eligible), or hepatitis C infection
- Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) ≥4
- Anti-thymocyte globulin (ATG) as part of the conditioning regimen
- Pregnancy
- Histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer within 30 days
- Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first chidamide treatment
- Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: Any history of ventricular fibrillation or torsade de pointes; Bradycardia defined as heart rate (HR)< 45 bpm (Patients with pacemakers are eligible if HR ≥ 45 bpm); Screening electrocardiogram (ECG) with a QTcF > 480 msec; Right bundle branch block + left anterior hemiblock (bifascicular block); Patients with myocardial infarction or unstable angina ≤ 12 months prior to starting study drug; Other clinically significant heart disease (e.g., New York Heart Association (NYHA) class III or IV , uncontrolled hypertension) as per discretion of principal investigator and/or treating physician; Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug with the exception of drugs listed on Appendix B of study documents that are required for hematopoietic cell transplantation (HCT) patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chidamide
Chidamide, tablets, 5 mg/tablet, 20 mg orally twice weekly from D-7~+14 Cyclophosphamide: 50 mg/Kg intravenously D+3, +4 Cyclosporine A: intravenously then orally 3 mg/Kg D+5~D+100
|
20 mg orally, twice weekly from D-7 to D+14
Other Names:
50 mg/Kg intravenously D+3, +4
3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
aGVHD
Time Frame: 100 day after infusion of PBSCs
|
accumulated incidence of aGVHD
|
100 day after infusion of PBSCs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GRFS
Time Frame: 3 years after recruitment
|
GVHD free, relapse free survival
|
3 years after recruitment
|
DFS
Time Frame: 3 years after recruitment
|
Disease free survival
|
3 years after recruitment
|
OS
Time Frame: 3 years after recruitment
|
Overall survival
|
3 years after recruitment
|
cGVHD
Time Frame: 2 yeas after infusion of PBSCs
|
accumulated incidence of cGVHD
|
2 yeas after infusion of PBSCs
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ting Liu, MD, West China Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclophosphamide
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- HX-GVHD-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MDS
-
Zhejiang Provincial Hospital of TCMUnknown
-
Assiut UniversityUnknown
-
Groupe Francophone des MyelodysplasiesNovartisUnknown
-
Rigshospitalet, DenmarkRecruiting
-
GWT-TUD GmbHRecruiting
-
University Hospital TuebingenRecruiting
-
Montefiore Medical CenterRecruitingAML | MDSUnited States
-
The Second Hospital of Shandong UniversityNot yet recruiting
-
Groupe Francophone des MyelodysplasiesAstex Pharmaceuticals, Inc.Active, not recruiting
-
M.D. Anderson Cancer CenterRecruiting
Clinical Trials on Chidamide
-
Huiqiang HuangUnknownLymphoma, Extranodal NK-T-Cell | EBV
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Sun Yat-sen UniversityRecruitingTriple Negative Breast CancerChina
-
Sun Yat-sen UniversityUnknown
-
Zhejiang UniversityRecruitingT Lymphoblastic Leukemia/LymphomaChina
-
Sichuan UniversityRecruiting
-
Cancer Institute and Hospital, Chinese Academy...UnknownNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRelapsed/Refractory PTCLT With at Least One Line of Prior Systemic TherapyChina
-
Liling ZhangCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingNewly Diagnosed Peripheral T-cell LymphomaChina
-
Peking UniversityPeking University International Hospital; Hebei Medical University Fourth HospitalUnknown